Here are this week’s stock briefs for Pfizer Inc. (NYSE:PFE). Pfizer Inc. (NYSE:PFE) stocks ended the week at 16.46 (as of 9/3/2010).

Weekly News Roundup: Pfizer Inc. (NYSE:PFE)

Monday 30 August

An unlikely product has made Pfizer Inc. (NYSE:PFE) confident in its future profits. Pfizer Inc. (NYSE:PFE) is doing well despite the recession thanks to erectile dysfunction drugs like Viagra and its clones, which created a multibillion-dollar industry just years ago.

Now the next generation of sex drugs, including ‘female Viagra,’ is on the way.

Wednesday 1 September

Pfizer Inc. (NYSE:PFE) and Bristol-Myers Squibb have been working on an experimental new drug that reduces the risk of stroke by more than half compared with aspirin, with no significant rise in major bleeding, reports said on Tuesday.

The drug, Apixaban, is an anticoagulant aimed at helping reduce the chances of stroke in patients with a common heart arrhythmia called atrial fibrillation (AF).

Apixaban will be a vast improvement over its predecessor Wafarin.

We will continue checking the Pfizer Inc. (NYSE:PFE) stock price for developments over the next few weeks.